{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T20:34:50Z","timestamp":1771014890561,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"vor","delay-in-days":366,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","valueinhealthjournal.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.jval.2014.12.017","type":"journal-article","created":{"date-parts":[[2015,3,13]],"date-time":"2015-03-13T02:18:42Z","timestamp":1426213122000},"page":"189-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Comparing the Cost-Effectiveness of Rituximab Maintenance and Radioimmunotherapy Consolidation versus Observation Following First-Line Therapy in Patients with Follicular Lymphoma"],"prefix":"10.1016","volume":"18","author":[{"given":"Qiushi","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Turgay","family":"Ayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loretta J.","family":"Nastoupil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam C.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2014.12.017_bib1","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma","volume":"89","author":"Chan","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.jval.2014.12.017_bib2","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.jval.2014.12.017_bib3","unstructured":"Howlader N, Noone AM, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975-2011. Bethesda, MD: National Cancer Institute, 2014"},{"key":"10.1016\/j.jval.2014.12.017_bib4","first-page":"786","article-title":"ACR Appropriateness Criteria\u00ae: localized nodal indolent lymphoma","volume":"27","author":"Hoppe","year":"2013","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.jval.2014.12.017_bib5","article-title":"Initial therapeutic strategy in follicular lymphoma (FL): an analysis from the National LymphoCare Study (NLCS)","author":"Friedberg","year":"2006","journal-title":"Presented at: ASCO Annual Meeting Proceedings"},{"key":"10.1016\/j.jval.2014.12.017_bib6","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/ajh.23313","article-title":"Follicular lymphoma: 2012 update on diagnosis and management","volume":"87","author":"Freedman","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jval.2014.12.017_bib7","article-title":"Cost of follicular lymphoma (FL) in Medicare patients","author":"Gleeson","year":"2008","journal-title":"Presented at: ASCO Annual Meeting Proceedings"},{"key":"10.1016\/j.jval.2014.12.017_bib8","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.hoc.2008.07.013","article-title":"Follicular lymphoma: clinical features and treatment","volume":"22","author":"Tan","year":"2008","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jval.2014.12.017_bib9","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.beha.2011.03.003","article-title":"Treatment strategies in advanced stage follicular lymphoma","volume":"24","author":"van Oers","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.jval.2014.12.017_bib10","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3816\/CLML.2010.n.086","article-title":"A decade of progress in lymphoma: advances and continuing challenges","volume":"10","author":"Flowers","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jval.2014.12.017_bib11","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90\u2013labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2014.12.017_bib12","doi-asserted-by":"crossref","first-page":"iv35","DOI":"10.1093\/annonc\/mdn191","article-title":"New response criteria for lymphomas in clinical trials","volume":"19","author":"Cheson","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jval.2014.12.017_bib13","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","article-title":"Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study","volume":"27","author":"Hochster","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2014.12.017_bib14","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2014.12.017_bib15","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1200\/JCO.2012.45.6400","article-title":"90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-Line Indolent trial","volume":"31","author":"Morschhauser","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2014.12.017_bib16","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with yttrium-90\u2013ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2014.12.017_bib17","first-page":"3319","article-title":"Health-related quality of life in patients with advanced-stage follicular lymphoma receiving consolidation with 90Y-ibritumomab tiuxetan (Zevalin(R)) of first remission: results from the randomized phase 3 First-Line Indolent Trial (FIT)","volume":"110","author":"Gondek","year":"2007","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.jval.2014.12.017_bib18","volume":"122","author":"Canales","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jval.2014.12.017_bib19","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/cncr.28659","article-title":"The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States","volume":"120","author":"Nastoupil","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.jval.2014.12.017_bib20","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1200\/JCO.2009.26.8748","article-title":"Radioimmunotherapy of lymphoma: a treatment approach ahead of its time or past its sell-by date?","volume":"28","author":"Illidge","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2014.12.017_bib21","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.clinthera.2012.02.019","article-title":"Economic evaluation of sequential treatments for follicular non-Hodgkin lymphoma","volume":"34","author":"Soini","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.jval.2014.12.017_bib22","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.3109\/10428194.2012.694429","article-title":"Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy","volume":"53","author":"Hornberger","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jval.2014.12.017_bib23","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) research data (1973-2011). In: SSB, ed., Surveillance Research Program. National Cancer Institute, DCCPS, April 2014, based on the November 2013 submission. Bethesda, MD: National Cancer Institute, 2014."},{"key":"10.1016\/j.jval.2014.12.017_bib24","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jval.2014.12.017_bib25","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin\u2019s lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2014.12.017_bib26","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0272989X9301300409","article-title":"Markov models in medical decision making: a practical guide","volume":"13","author":"Sonnenberg","year":"1993","journal-title":"Medical Decis Making"},{"key":"10.1016\/j.jval.2014.12.017_bib27","unstructured":"Archived Consumer Price Index detailed report information. 2013. Available from: http:\/\/www.bls.gov\/cpi\/cpi_dr.htm. [Accessed September 1, 2013]."},{"key":"10.1016\/j.jval.2014.12.017_bib28","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2005"},{"key":"10.1016\/j.jval.2014.12.017_bib29","first-page":"1","article-title":"United States life tables, 2007","volume":"59","author":"Arias","year":"2011","journal-title":"Natl Vital Stat Rep"},{"key":"10.1016\/j.jval.2014.12.017_bib30","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3310\/hta16370","article-title":"Rituximab for the first-line treatment of stage III\u2013IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation","volume":"16","author":"Papaioannou","year":"2012","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jval.2014.12.017_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/S1098-3015(10)63491-2","article-title":"Utility elicitation in patients with follicular lymphoma","volume":"9","author":"Wild","year":"2006","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2014.12.017_bib32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/11314070-000000000-00000","article-title":"Cost effectiveness of rituximab maintenance therapy in follicular lymphoma","volume":"28","author":"Deconinck","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2014.12.017_bib33","doi-asserted-by":"crossref","first-page":"492","DOI":"10.18553\/jmcp.2010.16.7.492","article-title":"What is the price benchmark to replace average wholesale price (AWP)?","volume":"16","author":"Curtiss","year":"2010","journal-title":"J Manag Care Pharmacy"},{"key":"10.1016\/j.jval.2014.12.017_bib34","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1586\/14737167.5.2.153","article-title":"Practical approach for using Medicare data to estimate costs for cost-effectiveness analysis","volume":"5","author":"Tumeh","year":"2005","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.jval.2014.12.017_bib35","unstructured":"Medicare physician fee schedule. 2013. Available from: http:\/\/www.cms.gov\/apps\/physician-fee-schedule\/. [Accessed September 1, 2013]"},{"key":"10.1016\/j.jval.2014.12.017_bib36","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1177\/0272989X12458348","article-title":"Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group\u20136","volume":"32","author":"Briggs","year":"2012","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2014.12.017_bib37","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/0272989X0002000113","article-title":"An assessment of methods to combine published survival curves","volume":"20","author":"Earle","year":"2000","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2014.12.017_bib38","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/JCO.2012.42.4101","article-title":"Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus 131iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016","volume":"31","author":"Press","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2014.12.017_bib39","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1200\/JCO.2006.05.8198","article-title":"Phase II trial of CHOP chemotherapy followed by tositumomab\/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin\u2019s lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911","volume":"24","author":"Press","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2014.12.017_bib40","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S1470-2045(08)70039-1","article-title":"Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ)","volume":"9","author":"Zinzani","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jval.2014.12.017_bib41","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1200\/JCO.2009.27.8325","article-title":"Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study","volume":"28","author":"Link","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2014.12.017_bib42","doi-asserted-by":"crossref","first-page":"7088","DOI":"10.1158\/1078-0432.CCR-08-0529","article-title":"Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma","volume":"14","author":"Jacobs","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jval.2014.12.017_bib43","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1200\/JCO.2005.14.803","article-title":"Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma","volume":"23","author":"Leonard","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2014.12.017_bib44","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3816\/CLM.2009.n.044","article-title":"Rituximab plus short-duration chemotherapy followed by yttrium-90 ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium","volume":"9","author":"Hainsworth","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.jval.2014.12.017_bib45","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/10428190701769665","article-title":"Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma","volume":"49","author":"Hornberger","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jval.2014.12.017_bib46","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1524-4733.2009.00676.x","article-title":"An evaluation of the cost\u2010effectiveness of rituximab in combination with chemotherapy for the first\u2010line treatment of follicular non\u2010Hodgkin\u2019s lymphoma in the UK","volume":"13","author":"Ray","year":"2010","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2014.12.017_bib47","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3111\/13696998.2013.873044","article-title":"Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin\u2019s lymphoma in England and Wales","volume":"17","author":"Dewilde","year":"2014","journal-title":"J Med Econ"},{"key":"10.1016\/j.jval.2014.12.017_bib48","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/ejh.12264","article-title":"Cost\u2010effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population\u2010based study","volume":"92","author":"Blommestein","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jval.2014.12.017_bib49","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.transci.2013.05.024","article-title":"Rituximab maintenance versus radio-immunotherapy consolidation in first remission follicular non-Hodgkin lymphoma","volume":"49","author":"Hagenbeek","year":"2013","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.jval.2014.12.017_bib50","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1200\/JCO.2006.07.0409","article-title":"Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin\u2019s disease","volume":"24","author":"Guadagnolo","year":"2006","journal-title":"J Clinical Oncol"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301515000108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301515000108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T20:37:00Z","timestamp":1598819820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301515000108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S1098301515000108"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2014.12.017","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing the Cost-Effectiveness of Rituximab Maintenance and Radioimmunotherapy Consolidation versus Observation Following First-Line Therapy in Patients with Follicular Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2014.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}